If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Mallard Acquisition (MACUU)
MingZhu Logistics Holdings (YGMZ)
Good Works Acquisition (GWACU)
Bull Horn Holdings (BHSEU)
Decarbonization Plus Acquistion (DCRBU)
Horizon Acquisition II (HZON.U)
Helix Acquisition (HLXA)
Datto Holding Corp. (MSP)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Foghorn Therapeutics Inc. (FHTX)
Gatos Silver, Inc. (GATO)
Priced IPO
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
fuboTV Inc. (FUBO)
Presidio Property Trust (SQFT)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
C4 Therapeutics, Inc. (CCCC)
Oncorus, Inc (ONCR)
More companies

Tarsus Pharmaceuticals, Inc. (TARS)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives. Their lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Blepharitis is a condition characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes in Demodex blepharitis. According to published studies, there are an estimated 20 million patients in the United States who suffer from blepharitis, with approximately 45%, or approximately nine million, of cases caused by Demodex infestation. To date, they have completed four Phase 2 trials for TP-03 in Demodex blepharitis, all of which met their primary, secondary and/or exploratory endpoints, as applicable, and during which TP-03 was well tolerated. They have commenced their Phase 2b/3 trial, Saturn-1, in September 2020, and intend to commence their Phase 3 trial, Saturn-2, in 2021, both with primary and secondary endpoints consistent with those of their Europa and Io Phase 2 trials.
Bobak Azamian Leo M. Greenstein
Employees Founded
12 2016


Address: 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618

Telephone: (949) 409-9820

Web page:

IPO information

Expected Date 10/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $300.8
Revenues (MM) $0
Net Income (Loss) (MM) $-7.3


What do you think will happen with the TARS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 5
Shares Revised (MM) 5.5
Expected offer amount (MM) $80
Realized offer amount(MM) $88
BofA Securities/ Jefferies/ Raymond James
LifeSci Capital/ Ladenburg Thalmann

Sector: Healthcare

Tweets about $TARS

Tweets volume:

RT volume:


Google Trends Stats